BANK VONTOBEL/CALL/ELI LILLY & CO/500/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 11:14:44 24/05/2024 pm IST | ||
| 28.79 EUR | -0.83% |
|
| Current month | +8.60% | ||
| 1 month | +27.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 28.79 | -0.83% |
| 23/24/23 | 29.03 | +3.53% |
| 22/24/22 | 28.04 | -1.68% |
| 21/24/21 | 28.52 | +8.69% |
| 20/24/20 | 26.24 | +3.43% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 11:14 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU9JAG |
| ISIN | DE000VU9JAG7 |
| Date issued | 05/07/2023 |
| Strike | 500 $ |
| Maturity | 21/06/2024 (28 Days) |
| Parity | 10 : 1 |
| Emission price | 3.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.2 € |
|---|---|
| Lowest since issue | 2.42 € |
| Spread | 0.02 € |
| Spread % | 0.07% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- Warrant
